Investing
The Zacks Analyst Blog Highlights Intel, Anheuser-Busch InBev, HCA Healthcare, Moderna and DuPont de
Published:
Last Updated:
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Intel Corp. INTC, Anheuser-Busch InBev SA/NV BUD, HCA Healthcare, Inc. HCA, Moderna, Inc. MRNA and DuPont de Nemours, Inc. DD.
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for Intel, Anheuser-Busch and HCA Healthcare
The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 12 major stocks, including Intel Corp., Anheuser-Busch InBev SA/NV and HCA Healthcare, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Intel shares have lagged the Zacks Semiconductor industry this year (+35.7% vs. +69.1%), but they have handily outperformed the broader (+35.7% vs. +12.9% for the S&P 500 index). The company is focusing on establishing an advanced semiconductor manufacturing ecosystem and has expanded its production capabilities in Germany and Poland under its IDM 2.0 (integrated device manufacturing) strategy.
A concerted focus on increasing market diversification and healthy momentum in data center business are tailwinds. Intel is also expanding its foundry services through partnership with Tower Semiconductor. The launch of its glass substrates for advanced packaging of chips is another positive.
However, contraction in the total addressable market across all CPU market segments is a major headwind. Weak demand trends and sluggish recovery in China are hurting sales in Network and Edge Group. Macroeconomic challenges, inventory adjustments and intense market volatility are straining margins.
(You can read the full research report on Intel here >>>)
Shares of Anheuser-Busch have outperformed the Zacks Beverages – Alcohol industry over the past year (+17.9% vs. -4.1%). The company has been benefiting from continued consumer demand for its brand portfolio. The company’s relentless execution, investment in brands and accelerated digital transformation aided top-line growth in second-quarter 2023.
The top line also benefited from strength of the beer category globally. The expansion of the Beyond Beer portfolio, and investments in B2B platforms, e-commerce and digital marketing bode well. For 2023, AB InBev expects EBITDA growth of 4-8%, in line with our estimate of 4%. It anticipates revenue growth to be higher than EBITDA growth, compared to our estimate 6% growth.
However, shares of AB InBev lagged the industry year to date. The stock came under pressure due to dismal earnings in the second quarter. AB InBev’s EBIT margin declined in the second-quarter, driven by higher cost of sales and SG&A expenses.
(You can read the full research report on Anheuser-Busch here >>>)
HCA Healthcare shares have outperformed the Zacks Medical – Hospital industry over the past year (+28.4% vs. +23.7%). The company’s revenues remain on an uptick on the back of a surge in admissions, outpatient surgeries and other procedures. Significant growth in its Managed Medicare operations is expected to drive its performance.
Multiple buyouts aided it in increasing patient volumes, enabled network expansion and added hospitals to its portfolio. It has been gaining from its telemedicine business line on the back of the rising digitization trend. HCA Healthcare resorts to prudent capital deployment via share buybacks and dividend payments.
However, the company’s escalating operating expenses have been weighing on the margins. A high debt level induces rise in interest expenses. As such, the stock warrants a cautious stance.
(You can read the full research report on HCA Healthcare here >>>)
Other noteworthy reports we are featuring today include Moderna, Inc. and DuPont de Nemours, Inc.
Intel Corporation (INTC): Free Stock Analysis Report
DuPont de Nemours, Inc. (DD): Free Stock Analysis Report
Moderna, Inc. (MRNA): Free Stock Analysis Report
Anheuser-Busch InBev SA/NV (BUD): Free Stock Analysis Report
HCA Healthcare, Inc. (HCA): Free Stock Analysis Report
To read this article on Zacks.com click here.
This article originally appeared on Zacks
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
